NCT00857896 - Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Overactive BladderNeurogenic Detrusor Overactivity

Interventions

DRUG

Fesoterodine

4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8

Trial Locations (9)

Pfizer Investigational Site, Cleveland

Pfizer Investigational Site, Liberty Township

Pfizer Investigational Site, Cincinnati

Pfizer Investigational Site, Troy

Pfizer Investigational Site, Overland Park

Pfizer Investigational Site, Overland Park

Pfizer Investigational Site, Little Rock

Pfizer Investigational Site, Long Beach

Pfizer Investigational Site, Shreveport